When the FDA grants a drug breakthrough therapy designation, it's usually a signal that something serious is finally being taken seriously. In this case, the drug is daridorexant, an orexin receptor antagonist already approved for adults, and the condition is pediatric insomnia. The designation is a milestone. It's also an admission: right now, there is no FDA-approved medication for insomnia in children. Not one.
For the millions of families dealing with a child who can't fall asleep, stay asleep, or function the next day, that gap isn't abstract. It's the reason parents have been left navigating a patchwork of off-label prescriptions, supplements with thin evidence, and behavioral strategies of wildly varying quality. Medicine hasn't had a clear answer. That's the honest starting point.
What the Daridorexant Designation Actually Means
Breakthrough therapy status doesn't mean the drug is approved or even proven to work in children. It means the FDA has agreed the preliminary evidence is promising enough to accelerate its review process. Daridorexant works by blocking orexin, a neuropeptide that promotes wakefulness. In adults, it received full approval in 2022 after demonstrating meaningful improvements in sleep onset and maintenance without the dependency risks associated with older sedative-hypnotics.
Whether those results translate to children, and to which age groups, remains to be established through pediatric trials now in progress. The FDA's designation essentially says: this is worth finding out faster. That's meaningful. But it also sets a clock on a problem that families have been living with for years without adequate clinical support.
Childhood insomnia is more common than most people assume. Studies consistently estimate that between 20% and 30% of young children experience sleep problems significant enough to affect daytime functioning, and rates in adolescents may be higher still. The absence of approved pharmacological treatment hasn't made the problem disappear. It's pushed it elsewhere.
Where Families Have Actually Turned
Without a prescription option, parents have largely relied on three things: melatonin, behavioral interventions, and hope. Melatonin is the most widely used. In the US and UK, it's sold over the counter, and surveys suggest a significant proportion of children now use it regularly. The evidence for melatonin in children with certain neurodevelopmental conditions, particularly ADHD and autism spectrum disorder, is reasonably solid. For otherwise healthy children with behavioral insomnia, the evidence is thinner and the long-term data in pediatric populations essentially doesn't exist.
Off-label use of prescription sedatives and antihistamines has also been common, driven by desperate parents and well-meaning clinicians working without formal guidance. These approaches carry real risks, including residual sedation, tolerance, and in some cases rebound insomnia. The FDA's silence on pediatric sleep drugs hasn't been protective. It's left a vacuum that's been filled with less regulated alternatives.
The behavioral approach has fared considerably better in the research. And that's the part of this story worth spending real time on.
What the Evidence Actually Supports
Cognitive behavioral therapy for insomnia, commonly known as CBT-I, is the most evidence-backed intervention available for sleep problems in both adults and children. In pediatric populations, it's typically adapted into what clinicians call behavioral sleep interventions, which target the habits, routines, and associations that drive poor sleep rather than the sleep problem itself.
A substantial body of research, including multiple systematic reviews, supports behavioral interventions as the first-line approach for childhood insomnia. The American Academy of Sleep Medicine has formally recommended them over pharmacological treatment precisely because the evidence is stronger and the safety profile is unambiguous. These interventions work. The challenge is access and consistency.
The core components of behavioral sleep treatment in children break down into several well-studied areas:
- Sleep hygiene: Consistent wake times, age-appropriate total sleep targets, and limiting stimulating activity close to bedtime. The fundamentals are unglamorous and effective.
- Bedtime fading: Temporarily delaying bedtime to match when the child is actually falling asleep, then gradually moving it earlier. This builds sleep pressure and reduces the anxiety that accumulates around prolonged bedtime struggles.
- Extinction and graduated extinction: Structured approaches to reducing parental involvement in sleep onset, ranging from abrupt removal to slow, stepwise withdrawal. These are some of the most studied strategies in pediatric sleep literature and consistently show results.
- Environmental controls: Cool, dark, quiet sleep environments. White noise where appropriate. Separating the bed from waking activities wherever possible.
- Screen reduction before bed: Blue light from devices suppresses melatonin production and delays circadian timing. This is one of the most modifiable and most ignored factors in adolescent sleep disruption.
None of these strategies require a prescription or a clinical trial. They do require sustained effort, parental buy-in, and enough support to implement them consistently. That's often the hardest part.
Screen Time, Schedules, and the Circadian Clock
It's worth pausing on screens, because the data has become hard to ignore. Studies tracking adolescent sleep over the past decade consistently find that device use in the hour before bed is one of the strongest behavioral predictors of delayed sleep onset and reduced total sleep time. It's not simply a matter of blue light. The content itself, particularly social media, is associated with heightened arousal and anxiety that extends well past the moment the phone is put down.
The research on consistent sleep schedules is equally clear. Irregular sleep timing, shifting bedtimes and wake times across the week, disrupts the circadian system in ways that compound over time. Irregular sleep schedules are associated with measurably higher cardiovascular risk, and the same circadian disruption that creates that risk in adults begins forming in childhood and adolescence. Getting a child to a consistent schedule isn't just about tonight's sleep. It's building a pattern that shapes their biology for years.
The quality of sleep matters as much as the quantity. Deep sleep plays a critical role in memory consolidation and neurological protection, and children, whose brains are actively developing, have more to lose when sleep architecture is chronically disrupted. This isn't a minor inconvenience. It's a developmental input.
What Parents Often Miss
Several factors show up repeatedly in pediatric sleep research that don't get enough attention in mainstream coverage.
First, parental sleep behavior matters. Children model what they observe. A household where adults are scrolling until midnight and sleeping inconsistently is an environment where it's very hard to build a child's sleep discipline, no matter how firm the rules are on paper.
Second, diet and nutrition intersect with sleep in ways that are increasingly supported by evidence. High intake of ultra-processed foods is associated with worse sleep quality in children, and the pathways appear to involve both circadian disruption and inflammatory signaling. The relationship between ultra-processed foods and children's brain health extends into sleep and cognitive function in ways that are still being mapped but are already relevant to daily decisions.
Third, anxiety is a major driver of pediatric insomnia that frequently goes unaddressed. A child who can't stop thinking at bedtime isn't simply refusing to sleep. They may need help with the cognitive and emotional content of those thoughts, not just the schedule around them. Behavioral sleep interventions that don't address anxiety tend to underperform in this population.
The Adult Parallel
Everything the evidence recommends for children, consistent schedules, reduced screen exposure, cool dark environments, decoupling wakefulness from the bed, is exactly what the evidence recommends for adults. Good sleep is one of the most powerful levers available for protecting long-term brain and cardiometabolic health, and the behavioral foundations don't change much across the lifespan.
This matters for two reasons. Adults implementing these practices for their children often see their own sleep improve. And the habits built in childhood, the circadian anchoring, the bedtime routine, the boundary around devices, tend to persist. What you build in a seven-year-old you're often still seeing reflected in that person at thirty.
The daridorexant trials may eventually deliver a safe and effective pharmacological option for children who don't respond to behavioral treatment. That would be genuinely valuable. Some children, particularly those with underlying neurological conditions, may need pharmacological support that currently doesn't exist in an approved form.
But for the majority of children with insomnia, and for the parents who've been waiting for medicine to catch up, the core message from the evidence hasn't actually changed: the behavioral tools work, they're safe, and they've been systematically underused because they're harder to prescribe than a pill.
The FDA designation is a prompt to accelerate drug development. It's also, inadvertently, a prompt to take seriously the approaches that don't require FDA approval at all.